MA44908A - Molécules d'arnsi et leur utilisation dans des procédés et des compositions pour inhiber l'expression du gène nrarp - Google Patents
Molécules d'arnsi et leur utilisation dans des procédés et des compositions pour inhiber l'expression du gène nrarpInfo
- Publication number
- MA44908A MA44908A MA044908A MA44908A MA44908A MA 44908 A MA44908 A MA 44908A MA 044908 A MA044908 A MA 044908A MA 44908 A MA44908 A MA 44908A MA 44908 A MA44908 A MA 44908A
- Authority
- MA
- Morocco
- Prior art keywords
- molecules
- arnsi
- inhibit
- compositions
- processes
- Prior art date
Links
- 101150057903 NRARP gene Proteins 0.000 title abstract 3
- 230000014509 gene expression Effects 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 206010029113 Neovascularisation Diseases 0.000 abstract 1
- 208000017442 Retinal disease Diseases 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000011190 diabetic macular edema Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 abstract 1
- 208000032253 retinal ischemia Diseases 0.000 abstract 1
- 208000029257 vision disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3235—Chemical structure of the sugar modified ring structure having the O of the ribose replaced by another atom
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/335—Modified T or U
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne des molécules d'arn si et leur utilisation dans des procédés et des compositions pharmaceutiques destinés à inhiber l'expression du gène nrarp. L'invention concerne également l'utilisation desdites molécules d'arn si dans le traitement et / ou la prévention d'une maladie ou d'un trouble lié à la néovascularisation caractérisé par une expression et / ou une activité accrue du gène nrarp, ledit trouble de la vue étant choisi dans le groupe comprenant dégénérescence maculaire apparentée (dmla), rétinopathie ischémique, œdème maculaire diabétique (dme), rétinopathie diabétique proliférante (pdr), ischémie rétinienne diabétique (dri), œdème rétinien diabétique (dre) et rétinopathie de prématurité (rop) et leurs combinaisons.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15382440 | 2015-09-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA44908A true MA44908A (fr) | 2018-07-18 |
Family
ID=54199152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA044908A MA44908A (fr) | 2015-09-08 | Molécules d'arnsi et leur utilisation dans des procédés et des compositions pour inhiber l'expression du gène nrarp |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US10752896B2 (fr) |
| EP (2) | EP4599889A2 (fr) |
| JP (3) | JP6946297B2 (fr) |
| KR (2) | KR102741279B1 (fr) |
| CN (2) | CN108026530B (fr) |
| AU (1) | AU2016319072B2 (fr) |
| CA (1) | CA2997648A1 (fr) |
| CO (1) | CO2018003596A2 (fr) |
| DK (1) | DK3347470T3 (fr) |
| ES (1) | ES3042567T3 (fr) |
| FI (1) | FI3347470T3 (fr) |
| HR (1) | HRP20251155T1 (fr) |
| IL (2) | IL295206B2 (fr) |
| LT (1) | LT3347470T (fr) |
| MA (1) | MA44908A (fr) |
| MX (2) | MX2018002857A (fr) |
| MY (1) | MY185638A (fr) |
| PL (1) | PL3347470T3 (fr) |
| PT (1) | PT3347470T (fr) |
| RS (1) | RS67288B1 (fr) |
| RU (1) | RU2738971C2 (fr) |
| SG (1) | SG10202002084UA (fr) |
| WO (1) | WO2017042238A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017104270A1 (fr) | 2015-12-15 | 2017-06-22 | 日立オートモティブシステムズ株式会社 | Dispositif de commande de véhicule |
| EP4560020A1 (fr) | 2023-11-22 | 2025-05-28 | Sylentis S.A.U. | Arnsi et compositions pour le traitement prophylactique et thérapeutique d'états rétiniens oculaires |
| EP4560019A1 (fr) | 2023-11-22 | 2025-05-28 | Sylentis S.A.U. | Arnsi et compositions pour le traitement prophylactique et thérapeutique d'états rétiniens oculaires |
| CN120137968B (zh) * | 2025-02-13 | 2025-12-09 | 上海市第一人民医院 | Rna、药物组合物、缀合物及应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| US20040259247A1 (en) | 2000-12-01 | 2004-12-23 | Thomas Tuschl | Rna interference mediating small rna molecules |
| US20060040262A1 (en) * | 2002-12-27 | 2006-02-23 | Morris David W | Novel compositions and methods in cancer |
| AU2003214363A1 (en) * | 2002-02-13 | 2003-09-04 | Axordia Limited | Method to modify differentiation of pluripotential stem cells |
| PT1527176E (pt) | 2002-08-05 | 2007-04-30 | Atugen Ag | Novas formas de muléculas de arn de interferência |
| DK2284266T3 (da) * | 2002-11-14 | 2014-01-13 | Thermo Fisher Scient Biosciences Inc | sIRNA-MOLEKYLE MOD TP53 |
| WO2005062937A2 (fr) | 2003-12-22 | 2005-07-14 | University Of Massachusetts | Procedes et compositions d'amelioration de l'efficacite de la specificite d'un siarn a extremite emoussee simple et double |
| GB0521716D0 (en) | 2005-10-25 | 2005-11-30 | Genomica Sau | Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases |
| GB0608838D0 (en) | 2006-05-04 | 2006-06-14 | Novartis Ag | Organic compounds |
| JP2010507387A (ja) | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | 新規のｓｉＲＮＡおよびその使用方法 |
| US20100292301A1 (en) | 2007-02-28 | 2010-11-18 | Elena Feinstein | Novel sirna structures |
| US8614309B2 (en) | 2007-10-03 | 2013-12-24 | Quark Pharmaceuticals, Inc. | Double-stranded RNA directed to CASP2 and methods of use thereof |
| KR101672563B1 (ko) | 2008-10-22 | 2016-11-03 | 쿠아크 파마수티칼스 인코퍼레이티드 | 안질환을 치료하는 방법 |
| CN102272307A (zh) * | 2008-11-21 | 2011-12-07 | 利莱恩斯生命科学有限公司 | siNA介导的VEGF-C和RhoA的敲低对VEGF-A分泌、血管生成和/或新血管生成的抑制 |
| JP2013501526A (ja) * | 2009-08-14 | 2013-01-17 | ジェネンテック， インコーポレイテッド | Ｖｅｇｆアンタゴニストに対する患者の応答をモニターするための生物学的マーカー |
| WO2011056005A2 (fr) | 2009-11-04 | 2011-05-12 | 성균관대학교산학협력단 | Nouvelle structure d'arnsi pour réduire au minimum les effets hors cible causés par des brins antisens, et utilisation de celle-ci |
| EP2390327A1 (fr) * | 2010-05-27 | 2011-11-30 | Sylentis S.A. | ARNsi et leur utilisation dans des procédés et des compositions pour le traitement et/ou la prévention de maladies oculaires |
| WO2012140234A1 (fr) * | 2011-04-13 | 2012-10-18 | Vib Vzw | Modulation du miarn dans les maladies caractérisées par une angiogenèse aberrante |
| US20130123330A1 (en) | 2011-07-15 | 2013-05-16 | Patrick Y. Lu | Dual Targeted siRNA Therapeutics for Treatment of Diabetic Retinopathy and Other Ocular Neovascularization Diseases |
| KR101535341B1 (ko) * | 2012-07-02 | 2015-07-13 | 한화케미칼 주식회사 | Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도 |
| KR20140085790A (ko) * | 2012-12-27 | 2014-07-08 | 한화케미칼 주식회사 | Ｎｏｔｃｈ 신호전달을 효과적으로 저해하는 ｄｌｌ４에 특이적인 신규한 인간 단일클론항체 |
| EP2865757A1 (fr) * | 2013-10-22 | 2015-04-29 | Sylentis, S.A.U. | ARNsi et leur utilisation dans des procédés et des compositions pour inhiber l'expression du gène PDK1 |
| EP2865756A1 (fr) * | 2013-10-22 | 2015-04-29 | Sylentis, S.A.U. | ARNsi et leur utilisation dans des procédés et des compositions pour inhiber l'expression du gène FLAP |
| EP2865758A1 (fr) * | 2013-10-22 | 2015-04-29 | Sylentis, S.A.U. | ARNsi et leur utilisation dans des procédés et des compositions pour inhiber l'expression du gène ORAI1 |
| CN105624159B (zh) * | 2016-02-22 | 2019-02-05 | 中国人民解放军第二军医大学 | 一种针对人EDIL3基因的siRNA及其应用 |
-
0
- MA MA044908A patent/MA44908A/fr unknown
-
2016
- 2016-09-07 MX MX2018002857A patent/MX2018002857A/es unknown
- 2016-09-07 RS RS20250916A patent/RS67288B1/sr unknown
- 2016-09-07 HR HRP20251155TT patent/HRP20251155T1/hr unknown
- 2016-09-07 US US15/757,051 patent/US10752896B2/en active Active
- 2016-09-07 PL PL16766270.9T patent/PL3347470T3/pl unknown
- 2016-09-07 WO PCT/EP2016/071122 patent/WO2017042238A1/fr not_active Ceased
- 2016-09-07 RU RU2018112453A patent/RU2738971C2/ru active
- 2016-09-07 KR KR1020237042846A patent/KR102741279B1/ko active Active
- 2016-09-07 SG SG10202002084UA patent/SG10202002084UA/en unknown
- 2016-09-07 CN CN201680052073.2A patent/CN108026530B/zh active Active
- 2016-09-07 KR KR1020187009930A patent/KR102708889B1/ko active Active
- 2016-09-07 ES ES16766270T patent/ES3042567T3/es active Active
- 2016-09-07 FI FIEP16766270.9T patent/FI3347470T3/fi active
- 2016-09-07 LT LTEPPCT/EP2016/071122T patent/LT3347470T/lt unknown
- 2016-09-07 DK DK16766270.9T patent/DK3347470T3/da active
- 2016-09-07 IL IL295206A patent/IL295206B2/en unknown
- 2016-09-07 EP EP25182462.9A patent/EP4599889A2/fr active Pending
- 2016-09-07 CN CN202210139558.2A patent/CN114632090B/zh active Active
- 2016-09-07 JP JP2018530967A patent/JP6946297B2/ja active Active
- 2016-09-07 MY MYPI2018000302A patent/MY185638A/en unknown
- 2016-09-07 EP EP16766270.9A patent/EP3347470B1/fr active Active
- 2016-09-07 PT PT167662709T patent/PT3347470T/pt unknown
- 2016-09-07 CA CA2997648A patent/CA2997648A1/fr active Pending
- 2016-09-07 IL IL257524A patent/IL257524B2/en unknown
- 2016-09-07 AU AU2016319072A patent/AU2016319072B2/en active Active
-
2018
- 2018-03-07 MX MX2022000554A patent/MX2022000554A/es unknown
- 2018-04-04 CO CONC2018/0003596A patent/CO2018003596A2/es unknown
-
2021
- 2021-09-14 JP JP2021149368A patent/JP7394815B2/ja active Active
-
2023
- 2023-08-10 JP JP2023131212A patent/JP2023144029A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hägg et al. | Adiposity as a cause of cardiovascular disease: a Mendelian randomization study | |
| MA43131B1 (fr) | Compositions et procédés d'inhibition de l'activité de l'arginase | |
| EA201990019A1 (ru) | Соединения и композиции для подавления активности shp2 | |
| SA518400356B1 (ar) | مثبطات الأرجيناز واستخداماتها العلاجية | |
| MA49726B1 (fr) | Formulation d'anticorps anti-cgrp | |
| MA41038A (fr) | Composés d'aminopyridyloxypyrazole | |
| MA39390B2 (fr) | Thérapie génique pour le traitement de la rétinite pigmentaire | |
| MX2022012524A (es) | Adeno-asociado para administracion terapeutica al sistema nervioso central. | |
| MX2018009752A (es) | 1,2,3,-triazoles sustituidos como moduladores de nmda selectivos de nr2b. | |
| MA39219B1 (fr) | Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique | |
| MA41179A (fr) | Composés inhibiteurs de parg | |
| MX2021015500A (es) | Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b. | |
| HK1253734A1 (zh) | 用作RORγ激动剂和用於治疗疾病的芳基二氢-2H-苯并[B][1，4]恶嗪磺酰胺和相关化合物 | |
| MA39082B2 (fr) | Méthodes et compositions pharmaceutiques pour exprimer un polynucléotide d'intérêt dans l'épithélium pigmentaire rétinien d'un sujet | |
| MA39359A1 (fr) | Composés d'isoindolinone utilisés comme modulateurs de gpr119 pour le traitement du diabète, de l'obésité et de troubles associés | |
| JOP20210330A1 (ar) | مركبات بيرازولو-بيريدين عطرية غير متجانسة مستبدلة واستخدامها كمعدِّلات لمستقبل الغلوتومات "glun2b" | |
| MA53665B1 (fr) | Agonistes du récepteur farnésoïde x et leurs utilisations | |
| CR20210580A (es) | Amidas depirazol-piridina sustituidos y su uso como moduladores del receptor glun2b | |
| MX2017002877A (es) | Compuestos terapeuticos como inhibidores del receptor de orexina-1. | |
| EA201891710A1 (ru) | Терапевтические соединения | |
| EA201792575A1 (ru) | Фармацевтические композиции леветирацетама пролонгированного высвобождения | |
| MA38678A1 (fr) | Dérivés nucléosidiques 4'-azido, 3'désoxy-3'-fluoro substitués | |
| MA45172B1 (fr) | Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées | |
| EP3760213C0 (fr) | Composition pharmaceutique pour prévenir ou traiter le cancer, comprenant comme principes actifs un virus anticancéreux et de l'hydroxyurée | |
| MX2022000554A (es) | Arnip y su uso en metodos y composiciones para la inhibicion de la expresion del gen nrarp. |